These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 26651553)

  • 21. [Do thiazolidinediones harm skeletal integrity?].
    Takeuchi Y
    Clin Calcium; 2008 May; 18(5):650-5. PubMed ID: 18445884
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of diabetes and its treatments on skeletal diseases.
    Yan W; Li X
    Front Med; 2013 Mar; 7(1):81-90. PubMed ID: 23377889
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of proliferative diabetic retinopathy with insulin use and microalbuminuria.
    Chu SH; Li AH
    Arch Ophthalmol; 2010 Jan; 128(1):146; author reply 146-7. PubMed ID: 20065240
    [No Abstract]   [Full Text] [Related]  

  • 24. Thiazolidinediones and fracture risk in patients with Type 2 diabetes.
    Betteridge DJ
    Diabet Med; 2011 Jul; 28(7):759-71. PubMed ID: 21672000
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men.
    Yaturu S; Bryant B; Jain SK
    Diabetes Care; 2007 Jun; 30(6):1574-6. PubMed ID: 17363747
    [No Abstract]   [Full Text] [Related]  

  • 26. Insights into bone fragility in diabetes: the crucial role of bone quality on skeletal strength.
    Yamamoto M
    Endocr J; 2015; 62(4):299-308. PubMed ID: 25797364
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased bone density and decreased bone turnover, but no evident alteration of fracture susceptibility in elderly women with diabetes mellitus.
    Gerdhem P; Isaksson A; Akesson K; Obrant KJ
    Osteoporos Int; 2005 Dec; 16(12):1506-12. PubMed ID: 15824889
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Our Evolving Understanding of the Relationship Between Diabetes and Bone.
    Kotwal A; Drake MT
    Am J Med Sci; 2017 Oct; 354(4):333-334. PubMed ID: 29078835
    [No Abstract]   [Full Text] [Related]  

  • 29. Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus.
    Bilezikian JP; Josse RG; Eastell R; Lewiecki EM; Miller CG; Wooddell M; Northcutt AR; Kravitz BG; Paul G; Cobitz AR; Nino AJ; Fitzpatrick LA
    J Clin Endocrinol Metab; 2013 Apr; 98(4):1519-28. PubMed ID: 23450056
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diabetes mellitus, bone mineral density, and fracture risk.
    Strotmeyer ES; Cauley JA
    Curr Opin Endocrinol Diabetes Obes; 2007 Dec; 14(6):429-35. PubMed ID: 17982347
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Skeletal Metabolism, Fracture Risk, and Fracture Outcomes in Type 1 and Type 2 Diabetes.
    Sellmeyer DE; Civitelli R; Hofbauer LC; Khosla S; Lecka-Czernik B; Schwartz AV
    Diabetes; 2016 Jul; 65(7):1757-66. PubMed ID: 27329951
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Diabetes and osteoporosis].
    Valkusz Z
    Orv Hetil; 2011 Jul; 152(29):1161-6. PubMed ID: 21712181
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Importance of Metabolic Memory in the Development of Vascular Complications in Diabetic Patients.
    Luna P; Guarner V; Farías JM; Hernández-Pacheco G; Martínez M
    J Cardiothorac Vasc Anesth; 2016 Oct; 30(5):1369-78. PubMed ID: 27256447
    [No Abstract]   [Full Text] [Related]  

  • 34. [Thiazolidinediones and skeletal health].
    Meier C; Bodmer M; Meier CR; Kraenzlin ME
    Rev Med Suisse; 2009 Jun; 5(207):1309-10, 1312-3. PubMed ID: 19626930
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bone loss and fracture risk associated with thiazolidinedione therapy.
    Riche DM; King ST
    Pharmacotherapy; 2010 Jul; 30(7):716-27. PubMed ID: 20575635
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diabetes and fracture healing: the skeletal effects of diabetic drugs.
    Simpson CM; Calori GM; Giannoudis PV
    Expert Opin Drug Saf; 2012 Mar; 11(2):215-20. PubMed ID: 22145960
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Daily practice using the guidelines for prevention and treatment of osteoporosis. Anti-diabetic agents and fracture risk].
    Okazaki R
    Clin Calcium; 2008 Aug; 18(8):1154-61. PubMed ID: 18677054
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of rosiglitazone on bone mineral density and remodelling parameters in Postmenopausal diabetic women: a 2-year follow-up study.
    Berberoglu Z; Yazici AC; Demirag NG
    Clin Endocrinol (Oxf); 2010 Sep; 73(3):305-12. PubMed ID: 20148906
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes.
    Aubert RE; Herrera V; Chen W; Haffner SM; Pendergrass M
    Diabetes Obes Metab; 2010 Aug; 12(8):716-21. PubMed ID: 20590749
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of Type 2 Diabetes Mellitus and Antidiabetic Medications on Bone Metabolism.
    Lee HS; Hwang JS
    Curr Diab Rep; 2020 Nov; 20(12):78. PubMed ID: 33247351
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.